0.2895USD+0.52%Mkt Cap: 28.98M USDP/E: —Last update: 2026-06-01
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and …
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap28.98M USD
Enterprise Value29.68M USD
Revenue (TTM)1.11M USD
Gross Profit619.00K USD
Net Income (TTM)-7.12M USD
Revenue/Share0.0130 USD
Last Price0.2895 USD
Fiscal Year EndMar 2025
MR QuarterMar 2026
Employees70
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.40
PEG—
EV/EBITDA-3.94
EV/Revenue26.83
P/S26.15
P/B4.66
EPS (TTM)-0.06
EPS (Forward)-0.09
52W Range
0.240019% of range0.5000
52W High0.5000 USD
52W Low0.2400 USD
Profitability
Gross Margin48.70%
Oper. Margin-775.39%
EBITDA Margin0.00%
Profit Margin-560.27%
ROE-112.50%
ROA-81.41%
Growth
Revenue Growth-3.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.07M USD
CapEx (TTM)316.00K USD
FCF Margin-227.97%
FCF Yield-8.70%
Net Debt682.00K USD
Net Debt/EBITDA-0.09
Balance Sheet
Debt/Equity0.04
Current Ratio1.32
Quick Ratio0.79
Book Value/Sh0.0620 USD
Cash/Share0.0020 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateApr 19, 2013
Analyst Consensus
Rating—
Target (Mean)4.125 USD
Target Range3.000 USD – 5.250 USD
# Analysts2
Ownership
Shares Out.100.09M
Float90.22M
Insiders9.68%
Institutions22.50%
Short Interest
Short Ratio0.6d
Short % Float2.27%
Short % Out.1.30%
Shares Short1.30M
Short (prev mo.)874.38K
Technical
SMA 500.2972 (-2.6%)
SMA 2000.3306 (-12.4%)
Beta0.50
S&P 52W Chg27.94%
Avg Vol (30d)1.98M
Avg Vol (10d)797.40K
Technical Indicators
RSI (14)42.3
MACD-0.0056
MACD Signal-0.0041
MACD Hist.-0.0015
BB Upper0.3300 USD
BB Middle0.2995 USD
BB Lower0.2689 USD
BB Width20.41%
ATR (14)0.0150 USD
Vol Ratio (20d)0.39x